
Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.

Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.